R35CA210098 (GAJEWSKI, THOMAS F)Dec 7, 2016 - Aug 31, 2030 NIH Overcoming resistance to anti-PD1 immunotherapy Role: Principal Investigator |
|
R01CA198496 (GAJEWSKI, THOMAS F)Dec 7, 2015 - Nov 30, 2016 NIH Germline and somatic variants associated with melanoma immunophenotype Role: Principal Investigator |
|
R01CA181160 (GAJEWSKI, THOMAS F)Jul 8, 2014 - May 31, 2019 NIH Host STING pathway in anti-tumor immunity Role: Principal Investigator |
|
R01CA161005 (GAJEWSKI, THOMAS F)Aug 1, 2012 - May 31, 2017 NIH EGR2 in T cell tolerance Role: Principal Investigator |
|
R01AI080745 (GAJEWSKI, THOMAS F)Jul 21, 2009 - Jun 30, 2011 NIH DGK in T Cell Regulation and Tolerance Role: Principal Investigator |
|
R21AI079373 (GAJEWSKI, THOMAS F)Jul 1, 2008 - Jun 30, 2010 NIH Deletion of inhibitory genes in post-thymic T cells to study immune tolerance Role: Principal Investigator |
|
R01CA127475 (GAJEWSKI, THOMAS F)Apr 1, 2007 - Jan 31, 2012 NIH Countering immune resistance in the melanoma tumor microenvironment Role: Principal Investigator |
|
R01CA118153 (GAJEWSKI, THOMAS F)Sep 28, 2006 - Jul 31, 2011 NIH T Cell Responsiveness and Homeostasis in Anti-Tumor Role: Principal Investigator |
|
R21AI059818 (GAJEWSKI, THOMAS F)Jul 1, 2004 - Jun 30, 2006 NIH Molecular Dissection of T Cell Anergy Role: Principal Investigator |
|
R01CA090575 (GAJEWSKI, THOMAS F)May 1, 2003 - Apr 30, 2007 NIH Multi-Peptide/IL 12 Melanoma Vaccine Role: Principal Investigator |
|
R21AI053886 (GAJEWSKI, THOMAS F)Sep 30, 2002 - Aug 31, 2004 NIH Technologies To Block Gene Expression in Normal T Cells Role: Principal Investigator |
|
R01AI047919 (GAJEWSKI, THOMAS F)Apr 1, 2001 - Mar 31, 2006 NIH Biochemical/Molecular Changes Upon Naive T Cell Priming Role: Principal Investigator |